Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Chimerix’s Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($0.97) EPS, FY2025 earnings at ($1.12) EPS and FY2026 earnings at ($1.06) EPS.

CMRX has been the subject of several other research reports. StockNews.com downgraded Chimerix from a hold rating to a sell rating in a research report on Tuesday, August 13th. Wedbush restated an outperform rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, August 13th.

Chimerix Price Performance

Chimerix stock opened at $1.02 on Wednesday. Chimerix has a 12 month low of $0.75 and a 12 month high of $1.30. The company has a market cap of $91.42 million, a price-to-earnings ratio of -1.10 and a beta of 1.20. The stock’s 50-day moving average is $0.88 and its 200-day moving average is $0.97.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same period in the previous year, the company posted ($0.21) earnings per share. Research analysts anticipate that Chimerix will post -0.85 EPS for the current year.

Institutional Trading of Chimerix

Several large investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Chimerix in the second quarter valued at about $137,000. Acadian Asset Management LLC boosted its stake in shares of Chimerix by 15.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 291,981 shares during the last quarter. Koshinski Asset Management Inc. purchased a new position in shares of Chimerix during the 1st quarter valued at approximately $42,000. Marquette Asset Management LLC grew its position in shares of Chimerix by 24.3% during the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 22,709 shares in the last quarter. Finally, Pale Fire Capital SE raised its holdings in Chimerix by 113.6% in the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 112,318 shares in the last quarter. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.